Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Xiamen Amoytop Biotech Co., Ltd.473 enrolled

Overview

In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled. HBsAg/anti-HBs level, HBeAg/anti-HBe level, Serum HBV DNA load and alanine transaminase level will be test every year from the second year to the fifth year after the ending of peginterferon alfa treatment, and long-term benefit of interferon treatment will be evaluated.

Study Type

OBSERVATIONAL

Enrollment

473

Conditions

Hepatitis B

Interventions

Peginterferon Alfa-2BDRUG

pre-received standard peginterferon alfa-2b therapy

Peginterferon Alfa-2ADRUG

pre-received standard peginterferon alfa-2a therapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Understand and sign the informed consent form. * Participated in NCT01760122 study (TB1211IFN) and has received at least 39 doses of peginterferon. Exclusion Criteria: * Conditions which in the opinion of the investigator should be precluded from the study(e.g., poor compliance).